A pretransplant test dose of i.v. BU was previously used in pediatric patients undergoing a reduced-intensity allogeneic hematopoietic SCT (HSCT). Here, we used a BU test dose in 23 adult patients who were not pancytopenic and underwent a myeloablative allogeneic HSCT prepared with fludarabine and i.v. BU (FluBU). Pharmacokinetics (PK) of BU were calculated after a test dose (0.8 mg/kg) was performed 2 weeks before transplant. Targeted BU area under the curve (AUC) range was 4800-5200 lM min. The mean BU dose calculated after the test dose was 3.5 ± 0.5 mg/kg. To validate the test dose, PK studies were repeated in 17 patients after the first dose of BU during the conditioning regimen. An AUC below the therapeutic value of 4000 lM min was observed in 23% of the patients receiving a wt-based dose and in 0% of patients whose dose was calculated on the basis of the test dose (P ¼ 0.03). In patients who had a test dose, a significant correlation (Po0.0001) between the first and subsequent doses of BU during the conditioning regimen was observed. Our findings may allow more centers to pursue transplant strategies with targeted BU by overcoming the time limitation for PK studies during the conditioning regimen.
Introduction
For decades, the most common myeloablative preparative regimens for allogeneic hematopoietic SCT (HSCT) included the combination of CY with either TBI or oral BU.
As oral BU resulted in very large variations in the blood levels of the drug, raising the issue of sub-or supratherapeutic dosage in patients undergoing an HSCT, strategies to target oral BU levels were established by performing pharmacokinetic (PK) studies after the first of 16 doses. 1, 2 The recently developed i.v. BU formulation is characterized by a more consistent bioavailability profile compared with the oral formulation. In fact, there is a direct linear relationship between the dose and area under the curve (AUC) with the i.v. formulation, thus allowing more predictable blood levels after a dose of 0.8 mg/kg of body wt given over 2 h and repeated every 6 h for a total of 16 doses. 3 A mean AUC of 1002 mM min per dose was reported for this dosing regimen. Schedules of 1.6 mg/kg every 12 h or 3.2 mg/kg every 24 h 4, 5 were evaluated as alternatives to the every 6 h regimen. The efficacy and predictable blood concentrations from 3.2 mg/kg once daily dosing were further validated in other studies. [6] [7] [8] [9] In addition, single-daily myeloablative doses of i.v. BU have been consistently reported to cause limited non-hematologic toxicity. 6, 7, 10, 11 However, despite the fact that i.v. BU PK is known to be linear, 3, 12 an interpatient variability of AUC levels still exists and can result in sub-or supratherapeutic levels of the drug at the time of transplant. To address this variable metabolism in patients, targeted dosing of i.v. BU can be performed by analyzing the PK after the first dose of BU and then modifying the subsequent doses, if necessary, provided that the PK results are available in a timely manner. When using a regimen with daily doses of BU, the PK results need to be obtained within 24-48 h to modify at least two of the remaining doses. To overcome this timing limitation, pretransplant test dose approaches were tested. 8, 13 In particular, a test dose of 0.8 mg/kg i.v. BU was given to pediatric patients before the reduced-intensity FluBu2 regimen and it was found to be useful in predicting a targeted conditioning dose. 13 In this study, we tested whether a test dose of i.v. BU at 0.8 mg/kg infused in adult patients 2 weeks before a myeloablative allogeneic HSCT would allow us to target a BU AUC of 4800 (range 4000-6000 mM min) during a conditioning regimen conditioned with FluBU. /day for 4 days followed by BU for 4 days, with daily doses targeted to achieve an AUC of 4800 mM min.
Patients and methods

Patients
Test dose and PK studies
To perform the BU test dose blood sampling, each patient was admitted for an elective 23-h observation in the transplant unit approximately 2 weeks before starting the conditioning regimen. The BU test dose was 0.8 mg/kg using the actual or adjusted body wt as previously described. 7 BU was administered as a 1-h i.v. infusion (rate: 0.8 mg/kg/h) through a central i.v. catheter. All patients were pre-medicated with 8 mg of ondansetron. Antiepileptic medications were not given before the test dose, whereas lorazepam 14 was used during the conditioning regimen. In addition, acetaminophen and itraconazole were never used immediately before or during i.v. BU therapy to avoid metabolic interferences. Blood specimens (2-3 ml) were drawn from a peripheral vein in the arm opposite to the central line where BU was infused. Eight serial blood samples were collected at the following times: immediately before BU administration, immediately after the completion of BU infusion, 15 and 30 min, 1, 2, 4 and 6 h after the BU infusion. The blood samples were immediately placed on wet ice and sent to the hospital laboratory where they were centrifuged for 10 min at 3000-3200 r.p.m. The plasma was collected in plastic tubes with screw caps, frozen at À20 1C and shipped out on dry ice to the Seattle Cancer Care BU monitoring pharmacokinetic laboratory. Given that BU has linear PK and that there is no known accumulation of the drug that would potentially affect concentrations of subsequent doses, 1,4 the conditioning dose for BU is considered to be fourfold the test dose. The BU conditioning dose was calculated by using the following formula: target AUC of 4800 (mM min) Â test dose (mg)/the test dose AUC (mM min). This calculated dose of BU for the conditioning regimen was administered over 3 h (rate: 1.06 mg/kg/h) and given daily for 4 days. To determine whether the test dose PK was an accurate predictor for achieving a targeted conditioning dose, BU PK was evaluated after the first conditioning dose (day 1 BU) and compared with the PK of the test dose. The results from the first conditioning dose (day 1) were received the day after the second BU dose had been administered. If required, the third and fourth doses were then adjusted on the basis of these results to achieve the target AUC.
Statistical analysis
Weight-based and test-based doses were compared by using the two-tailed P-value t-test or w 2 test. The third and fourth conditioning doses (adjusted on the basis of the results from day 1 PK) were compared with the first dose by linear regression analysis.
Results
Higher dose of i.v. BU based on test dose All 23 patients enrolled in this study received a BU test dose 2 weeks before starting the conditioning regimen. The mean AUC obtained was 1185 ± 400 mM min. On the basis of the test dose, a conditioning dose was calculated to target an AUC of 4800 mM min. Without including the initial test dose, the mean dose administered in the conditioning regimen was 3.5 ± 0.5 mg/kg/day and was higher than the standard dose of 3.2±0.1 mg/kg/day (P ¼ 0.03) that was calculated on the basis of the patient's body wt (Figure 1 ). Targeted AUC using the test dose In 17 of 23 patients who had received the test dose, we repeated the BU PK study after the first daily dose of BU during the conditioning regimen. The rates of infusion of i.v. BU during the test dose (0.8 mg/kg/h) and during the conditioning regimen (1.06 mg/kg/h) were similar. In six patients, we could not assess the BU AUC on day 1 of the preparative therapy because of the weekend scheduling or insurance reimbursement limitations. The average AUC measured after the first conditioning dose calculated on the basis of the test dose was 4992.1±1100 mM min. The dose of BU, based on body wt, administered for the test dose in these patients yielded AUCs that were below the therapeutic range of 4000 mM min in 23% of the cases (Figure 2a ), as compared with 0% after day 1 BU, calculated on the basis of the results of the test dose ( Figure 2b ) (P ¼ 0.03). AUC levels above 6000 mM min were observed in two patients receiving the test dose (AUC 6392 and 6420 mM min, respectively) and in two separate patients after day 1 BU (AUC 6054 and 6296 mM min, respectively). These latter two patients had CML and were both on treatment with a tyrosine kinase inhibitor at the time of the test dose but not at the time of the BU conditioning doses. The BU clearance remained similar between the test dose and day 1 of the conditioning treatment in the majority of patients (not shown). As after day 1 BU we obtained PK results within 48 h, we could further adjust the third and fourth doses of BU, if necessary. Therefore, we compared the first dose with the last two doses in all the patients and a significant correlation was detected by a linear regression analysis ( Figure 3 ). The mean first dose (3.5 ± 0.5 mg/kg/d) was not statistically different from the third or fourth doses (3.6±0.7 mg/kg/d) (P ¼ 0.9). These findings suggest that the conditioning dose calculated from the pretransplant test doses was accurate and that the test dose was a reliable predictor of the targeted AUC.
Test dose toxicity
None of the patients receiving the BU test dose experienced non-hematological toxicity. In particular, no episodes of epileptic activity or VOD were observed. Of the 23 patients, 10 had an average decrease in plt count of 37% from baseline. None of the patients reached a plt count lower than 50 Â 10 9 /l and no one experienced bleeding after the test dose. Two patients whose plt counts dropped below 70 Â 10 9 /l after the test dose already had a baseline plt count o150 Â 10 9 /l because of BM involvement by myelodysplasia and small lymphocytic lymphoma, respectively. The ANC also decreased by approximately 50% after the test dose in these patients. However, none of the patients experienced severe neutropenia (ANCo0.5 Â 10 9 /l) and/or febrile episodes.
Discussion
We here validate that a test dose of i.v. BU administered 2 weeks before starting the conditioning regimen is a reliable method of determining a patient-individualized targeted dose of BU in allogeneic myeloablative HSCT.
In our study, the target AUC for BU conditioning dose was 4800 mM min, and the mean AUC obtained from the first dose of BU based on the test dose was 4991.7 mM min. A previous study recommended a therapeutic BU AUC range between 4000 and 6000 mM min. 12 If we had not performed the test dose, 23% of the patients would have fallen below 4000 mM min and 12% above 6000 mM min. Using the test dose, no patients had a subtherapeutic AUC under 4000 mM min and two patients (12%) had an AUC above 6000 mM min. Interestingly, these patients were on tyrosine kinase inhibitors (dasatinib and nilotinib) at the time of the test dose but not at the time of the conditioning regimen. As these drugs can inactivate CYP3A4, the enzyme responsible for the oxidation of BU after initially being conjugated with glutathione, the hypothesis that tyrosine kinase inhibitors could affect BU metabolism cannot be excluded. [15] [16] [17] [18] Variations in BU AUC have been previously observed in approximately 20% of the patients. 3, 6, 7, 11, 12 In particular, these variations were higher in a pediatric population with rapidly changing metabolism, 13 and the test dose was used to address this problem before a reduced-intensity conditioning HSCT. In this study, we validated this method in adult patients receiving a myeloablative regimen. Among different factors contributing to variations in AUC, inconsistencies in blood-drawing procedures and specimen processing and handling could be included. To avoid falsely elevated BU levels in our study, we established the policy of drawing the blood for PK at a different site from where the BU was infused. Different methods of targeting BU are currently used and they depend on center-specific policies or on site technology to assess BU PK. 19, 20 PK of BU performed after the first day of the conditioning regimen permits the adjustment of all the subsequent doses if the turnaround time for obtaining the PK results is less than 24 h. Our institution could not perform BU assays on site and relied on an external laboratory for analysis. Results were available between 24 and 48 h. Therefore, we could only adjust the third and fourth doses of BU if required. Although all the patients received a test dose before transplant, in 22% of them, a BU PK could not be analyzed after the first dose of the conditioning regimen because i.v. BU was started over the weekend. Although in these cases we could perform the PK on the third day of treatment with BU, we could not adjust any further dose.
The argument of centers that prefer not to target i.v. BU is that at the present time it is a labor-intensive procedure that has not yet been shown to improve the outcome of transplant. To address this relevant question, it would be important that all transplant centers participate in future studies aimed at exploring the role of targeted i.v. BU both in autologous and allogeneic HSCT, by performing BU PK studies in the necessary time to adjust subsequent doses. However, if a timely interpretation of the BU PK for the first dose during the conditioning regimen is not possible because of staffing, scheduling or laboratory restrictions, a pretransplant test dose is a reliable alternative that could allow more transplant centers to pursue a patient-specific conditioning regimen with target doses of BU.
